Viatris Q2 2026 Results Showcase Pipeline Progress and Capital Returns

Viatris (Nasdaq: VTRS) published its second‑quarter 2026 financial results on August 6, 2026. The company delivered $3.8 billion in total revenues, marking a 5 % increase year‑over‑year on a reported basis and a 3.5 % operational growth from the same period in 2025. Adjusted EBITDA reached $1.2 billion, reflecting an 8 % operational gain. Despite reporting a U.S. GAAP net loss of $119 million, driven largely by a non‑cash charge associated with the sale of Tyrvaya® rights, Viatris raised the midpoints of its full‑year 2026 guidance across key metrics. The company returned approximately $550 million to shareholders through share repurchases and reduced its gross leverage ratio to 2.9x.

The quarter’s performance was bolstered by progress across Viatris’ pipeline. A major highlight: the FDA approved the Gwyn Lo™ once‑weekly contraceptive patch in July 2026, with commercial availability expected later this year. Additionally, Viatris executed a definitive agreement in August to sell the global rights to Tyrvaya® in exchange for a $30 million upfront payment and up to $70 million in contingent milestone payments. These strategic moves support Viatris’ focus on reallocating resources toward higher-growth opportunities.

However, Viatris continues to manage supply challenges: following a February fire and FDA Form 483 observations at its Nashik, India manufacturing facility, production has resumed but intermittent disruptions are expected to impact H2 2026 revenue by an estimated $100 million to $150 million.

Viatris’ capital return efforts included approximately $270 million in share repurchases through early August, with around $730 million remaining under its board‑authorized repurchase plan. The company also refinanced debt, repaying $900 million of maturing obligations and issuing €650 million in senior notes due 2033. With reduced leverage and ample liquidity, Viatris reinforced its financial flexibility.

This quarter underscores Viatris’ dual focus on pipeline advancement and disciplined capital management. The FDA approval of Gwyn Lo strengthens its women’s health portfolio, while the Tyrvaya® divestiture simplifies its business scope. Investors may monitor supply‑related headwinds from Nashik and execution of its elevated full‑year guidance as key indicators of sustained momentum.